In the rapidly evolving landscape of biotechnology, the study of synthetic chains has opened new doors for researchers. As someone deeply interested in the mechanics of molecular targeting, I have spent significant time reviewing the literature surrounding the AXT050 peptide. This specialized molecule represents a sophisticated approach to biomimetic design, serving as a focal point for those investigating how a novel integrin-binding peptide can influence cellular signaling pathways.
The Molecular Architecture of AXT050
At its core, AXT050 is a collagen-IV derived peptide. Its sequence, LRRFSTAPFAFIDINDVINF, is a 20-amino acid structure that has garnered attention for its high-affinity binding to tumor-associated integrins, such as $\alpha v\beta 3$ and $\alpha 5\beta 1$.
From my perspective as an enthusiast of laboratory-grade compounds, the precision of this sequence is what makes it so fascinating. Unlike generic compounds, the AXT050 peptide is engineered to inhibit Met-integrin interactions. By effectively acting as an by K Mashayekhi·2026—Anti-αvβ3 integrin peptides such as AXT050 and ψRGDechi are designed to prevent αvβ3 integrin downstream signaling, a receptor highly Read more HGF (hepatocyte growth factor) inhibitor, it disrupts the signaling cascades that are often the subject of intense aca by A Patil·2023·Cited by 1—For comparison, a similarpeptidein this family,AXT050, has a reported dissociation constant KD of 1 – 3 nM for binding with αvβ3 integrin [22,35]. We Read more demic study. When using labeled AXT050 peptide in controlled environments, researchers have observed its ability to localize with remarkable specificity.
Advanced Delivery Systems: PLGA-PEG Integration
One of the most compelling aspects of this field is the use of na Therapeutic potential of an antiangiogenic multimodal nocarriers. We by Y Huang·2023·Cited by 14—The AXT 050 peptide is a collagen-IV-derived peptide thatcan target tumor-associated integrinsand increase the accumulation of drugs in tumor cells (30). Here Read more often see AXT050 conjugated to PLGA-PEG NPs (nanoparticles) to enhance stability and circulation time. My review of rec On the cellular selectivity of targeting peptide-nanoparticle ent data suggests that PLGA-PEG nanoparticles with AXT050 as ligand exhibit a unique "biphasic relationship" regarding surface coating density.
For instance, studies have shown that a 10% peptide surface coating can significantly extend the half-life of these particles. This level of technical detail is crucial for anyone trying to understand how AXT050 peptide can improve the accumulation of therapeutic agents. Whether the particles are spherical or ellipsoidal, the inclusion of this ligand is a game-changer for those focusing on cellular selectivity.
Related Research: The AXT Series
It is impossible to discuss the AXT050 peptide without acknow Experimental Drug Delivers One-Two Punch to Vision Loss ledging its sibling, AXT107. While AXT050 is primarily recognized for its antitumor properties, AXT107, a collagen IV-derived peptide, is frequently cited for its role in ophthalmology.
* AXT107 functions by targeting VEGF pathways.
* It stops abnormal blood vessels in the eye from leaking vision-blocking fluids.
* This breakthrough has led to the development of therapies that help prevent or regress pathological new vessel formation in retinal diseases.
Both compounds underscore why the scientific community is so invested in peptides that can target tumor-ass On the cellular selectivity of targeting peptide-nanoparticle ociated integrins.
Personal Observations on Efficacy and Design
In my exploration of these materials, the AXT050 peptide treatment improves survival of mice with Myc-induced autochthonous liver tumors in preclinical models, highlighting the potential of these synthetic chains. It is important to note that the XT designation within the broader family of these molecules often signifies specific modifications to the collagen backbone to optimize binding kinetics, with a reported dissociation constant ($K_D$) in the 1–3 nM range for $\alpha v\beta 3$ integrin.
When looking at synthetic peptide may curb macular degeneration-based eye damage research, it becomes clear that AXT107 | SP2043 | Gersizangitide supplier |CAS 2417491- we are in a golden age of bio-engineering. Whether you are looking at the foundational work or the latest advancements in peptides, the trajectory of this technology remains incredibly promising.
As a final takeaway for those tracking these developments, the integration of peptide technology into targeted delivery platforms is not just a trend; it is a fundamental shift in how we approach biochemical interaction at the molecular level. The precision of the AXT050 sequence continues to serve as a benchmark for high-affinity, integrin-targeted research.